BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 524 filers reported holding BIO-TECHNE CORP in Q3 2022. The put-call ratio across all filers is 0.22 and the average weighting 0.2%.
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 46,500 | $13,206,000 | 5.33% |
Montanaro Asset Management Ltd | 101,950 | $28,954,000 | 4.43% |
Jackson Square Partners, LLC | 521,991 | $148,245,000 | 3.89% |
Sandhill Capital Partners LLC | 119,671 | $33,987,000 | 3.88% |
STONE RUN CAPITAL, LLC | 22,055 | $6,264,000 | 3.38% |
Ownership Capital B.V. | 610,466 | $173,372,000 | 3.35% |
Brown Capital Management | 823,303 | $233,818,000 | 3.28% |
DF DENT & CO INC | 671,348 | $190,663,000 | 2.94% |
Westwind Capital | 27,931 | $7,932,000 | 2.78% |
MAIRS & POWER INC | 673,620 | $191,308,000 | 2.41% |
Pembroke Management, LTD | 74,550 | $21,172,000 | 2.35% |
Summit Creek Advisors LLC | 59,992 | $17,038,000 | 2.35% |
Aristotle Atlantic Partners, LLC | 129,085 | $36,661,000 | 2.23% |
AMERICAN CAPITAL MANAGEMENT INC | 191,246 | $54,314,000 | 2.14% |
GENEVA CAPITAL MANAGEMENT LLC | 266,393 | $75,656,000 | 1.75% |
Select Equity Group, L.P. | 1,481,360 | $420,706,000 | 1.47% |
12 West Capital Management LP | 52,648 | $14,952,000 | 1.32% |
BAMCO INC /NY/ | 1,427,064 | $405,286,000 | 1.31% |
Winslow Capital Management, LLC | 690,742 | $196,170,000 | 1.15% |
Machina Capital S.A.S. | 1,785 | $507,000 | 1.07% |
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BIO-TECHNE CORP's shareholders in Q3 2022. To view BIO-TECHNE CORP's shareholder history, click here.